Evidence map›Paper›PMID 25035246›Full record

ArticleJournal of psychopharmacology (Oxford, England)2014

Efficacy of atomoxetine in adults with attention deficit hyperactivity disorder: an integrated analysis of the complete database of multicenter placebo-controlled trials.

Philip Asherson, Chris Bushe, Keith Saylor, Yoko Tanaka, Walter Deberdt, Himanshu Upadhyaya

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of psychopharmacology (Oxford, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 3 pooled it
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Live fast, die young? A review on the developmental trajectories of ADHD across the lifespan.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2018
    Review
  15. Treatment of adult ADHD: a clinical perspective.Therapeutic advances in psychopharmacology · 2018
    Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Philip AshersonMRC Social, Genetic and Developmental Psychiatry Centre, King's College London, London, UK philip.asherson@kcl.ac.uk.
Chris BusheEli Lilly and Co., Basingstoke, UK.
Keith SaylorNeuroscience Inc., Herndon, VA, USA.
Yoko TanakaEli Lilly and Co., Indianapolis, IN, USA.
Walter DeberdtEli Lilly and Co., Brussels, Belgium.
Himanshu UpadhyayaEli Lilly and Co., Indianapolis, IN, USA.
Eli Lilly (United States) · USEli Lilly (United Kingdom) · GBKing's College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Persistence of attention deficit hyperactivity disorder (ADHD) into adulthood can be disabling or lead to substantial impairment. Several clinical trials of atomoxetine (ATX) in adults with ADHD have been reported following the National Institute for Health and Clinical Excellence (NICE) guidelines issued in 2008. We performed an integrated analysis of all Eli Lilly-sponsored, randomized, double-blind, placebo-controlled studies of ATX in adults with ADHD completed as of May 2012. Individual patient data were pooled from six short-term (10-16 week) studies (1961 patients) and three longer-term (six-month) studies (1413 patients). In the short-term analysis, ATX patients achieved a significantly greater mean reduction in ADHD symptoms than placebo patients (-12.2 vs -8.1; Conners' Adult ADHD Rating Scale-Investigator-Rated: Screening Version (CAARS-Inv: SV); p<0.001). In the longer-term analysis, respective improvements after six months were -13.2 vs -9.7 (p<0.001). Response rates at study endpoints for ATX vs placebo, based on CAARS-Inv: SV improvement ≥ 30% and Clinical Global Impressions of ADHD-Severity (CGI-ADHD-S) ≤ 3 were 34.8% vs 22.3% in the short-term and 43.4% vs 28.0% after six months, and CAARS-Inv: SV improvements ≥ 40% were 41.3% vs 25.3% in the short-term and 44.0% vs 31.4% after six months (all p<0.001). Overall, ATX had a clinically significant effect in adults with ADHD, with reductions in core symptoms and clinically meaningful responder rates.

Indexed as

Multicenter Studies as TopicRandomized Controlled Trials as TopicAdrenergic Uptake InhibitorsAdultAtomoxetine HydrochlorideAttention Deficit Disorder with HyperactivityDatabases, PharmaceuticalDouble-Blind MethodFemaleHumansMalePropylaminesPsychiatric Status Rating ScalesTreatment OutcomeAdrenergic Uptake InhibitorsAtomoxetine HydrochloridePropylaminesadultsatomoxetineAttention deficit hyperactivity disorderpooled analysistreatment guidelines

Identifiers

PMID25035246
PMCPMC4230847
OpenAlexW2129129238

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.